#1 Clinical Trials Search in Europe

Psilocybine

This article examines the use of psilocybin, the active compound in “magic mushrooms,” in various clinical trials. Researchers are investigating psilocybin’s effects on brain function, consciousness, and its potential therapeutic applications for conditions like depression and anxiety. Studies range from exploring the drug’s neurobiological impacts to assessing its efficacy in improving mental well-being. The trials involve different dosages, administration methods, and combinations with other substances to better understand psilocybin’s mechanisms and optimize its potential benefits.

Table of Contents

What is Psilocybin?

Psilocybin is a naturally occurring psychoactive compound found in certain species of mushrooms, commonly known as “magic mushrooms”. It is being studied as a potential treatment for various mental health conditions. Psilocybin is also known by other names such as psilocybine, psilocibin, and benzodiazepine[1].

In medical research, psilocybin is typically synthesized in a laboratory to ensure purity and precise dosing. It works by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor, which can lead to altered states of consciousness and potential therapeutic effects[2].

Conditions Treated with Psilocybin

Research is exploring the use of psilocybin for treating several mental health conditions:

  • Major Depressive Disorder (MDD): Studies are investigating psilocybin’s potential to rapidly reduce depressive symptoms, especially in patients with cancer-related depression[3].
  • Anxiety Disorders: Psilocybin is being studied for its effects on reducing anxiety, particularly in patients with life-threatening illnesses[2].
  • Opioid Use Disorder (OUD): Researchers are exploring whether psilocybin can help individuals overcome opioid addiction when used alongside standard treatments like buprenorphine[4].
  • Basic Science Research: Some studies are investigating how psilocybin affects brain function and consciousness in healthy volunteers[2].

How Psilocybin Works

Psilocybin is thought to work by:

  • Altering brain connectivity: It may change how different parts of the brain communicate with each other, potentially allowing for new perspectives and breaking negative thought patterns[2].
  • Enhancing neuroplasticity: Psilocybin might increase the brain’s ability to form new connections and adapt, which could help in treating various mental health conditions[5].
  • Affecting serotonin receptors: By interacting with serotonin receptors, particularly 5-HT2A receptors, psilocybin can influence mood, perception, and cognition[2].

How Psilocybin is Administered

In clinical trials, psilocybin is typically administered in the following ways:

  • Oral capsules: Most studies use oral capsules containing precise doses of psilocybin, ranging from very low doses (1 mg) to higher doses (25-30 mg)[3][4].
  • Intravenous (IV) infusion: Some studies are exploring the use of IV psilocybin, particularly for investigating its effects on sleep and consciousness[6].

Psilocybin is usually given in controlled settings under medical supervision, often with psychological support before, during, and after the experience[4].

Effects of Psilocybin

The effects of psilocybin can vary depending on the dose and individual factors. Some potential effects include:

  • Altered state of consciousness: This may include changes in perception, thought patterns, and sense of self[2].
  • Emotional breakthroughs: Some people report experiencing intense emotions or gaining new insights into personal issues[6].
  • Changes in mood: Psilocybin may lead to improvements in mood and reductions in anxiety and depression symptoms[3].
  • Mystical-type experiences: Some individuals report having profound, spiritually significant experiences[6].

It’s important to note that these effects can be intense and may be challenging for some individuals. This is why psilocybin is administered in controlled settings in clinical trials[4].

Ongoing Research

Several clinical trials are currently investigating various aspects of psilocybin treatment:

  • Dosing strategies: Researchers are comparing different doses of psilocybin to determine the most effective and safe dosing regimens[3][4].
  • Combination with other treatments: Some studies are looking at how psilocybin works when combined with other therapies, such as buprenorphine for opioid use disorder[4].
  • Long-term effects: Researchers are investigating how long the potential benefits of psilocybin treatment may last[3].
  • Brain imaging studies: Some trials are using techniques like fMRI (functional magnetic resonance imaging) to understand how psilocybin affects brain activity and connectivity[2].

Safety Considerations

While psilocybin shows promise in clinical trials, it’s important to understand that:

  • Psilocybin is still considered an experimental treatment and is not yet approved for general medical use.
  • The use of psilocybin outside of controlled clinical settings can be dangerous and is illegal in many countries.
  • Psilocybin can interact with other medications and may not be suitable for people with certain mental health conditions or medical histories.
  • The long-term effects and potential risks of psilocybin treatment are still being studied[4][6].

Always consult with a healthcare professional before considering any new treatment, including participation in clinical trials involving psilocybin.

Aspect Details
Study Types Randomized, double-blind, placebo-controlled trials; Dose-response studies; Mechanistic studies
Conditions Studied Major depressive disorder, anxiety, healthy volunteers
Dosage Range 5mg to 40mg oral; Some studies use IV administration
Key Measures Brain activity (fMRI, EEG), mood scales, altered states of consciousness questionnaires, mystical experience measures
Safety Monitoring Vital signs, adverse effects, ECG changes
Pharmacokinetics Peak plasma concentration, time to peak, elimination half-life
Neurobiological Focus Serotonin 2A receptor activity, neuroplasticity, functional connectivity
Psychological Aspects Ego dissolution, mystical experiences, emotional breakthroughs, psychological insight
Long-term Effects Some studies assess persisting effects on mood, well-being, and personality traits

FAQ

  • What is psilocybin and how does it work? Psilocybin is the active compound found in 'magic mushrooms'. It acts primarily on serotonin 2A receptors in the brain. When ingested, psilocybin is rapidly converted to psilocin, which is responsible for its psychoactive effects. These effects can include alterations in mood, perception, and consciousness.
  • What conditions are being studied in psilocybin clinical trials? Clinical trials are investigating psilocybin's potential in treating various conditions, including major depressive disorder, anxiety, and addiction. Some studies also focus on its effects in healthy volunteers to better understand its impact on brain function and consciousness.
  • How is psilocybin administered in these trials? Psilocybin is typically administered orally in capsule form. Doses can range from low (5mg) to high (40mg). Some trials also use intravenous (IV) administration. The method and dosage depend on the specific study objectives.
  • Are there any risks or side effects associated with psilocybin use in clinical trials? While psilocybin is generally considered safe in controlled settings, it can cause temporary alterations in perception, mood, and cognition. Some participants may experience anxiety or challenging psychological experiences. Physical effects can include changes in blood pressure, heart rate, and nausea. Trials closely monitor participants for any adverse effects.
  • How long do the effects of psilocybin last in these studies? The acute effects of psilocybin typically last 4-6 hours, but can vary depending on the dose and individual. Some studies monitor participants for up to 24 hours after administration to assess both immediate and longer-lasting effects. Certain trials also investigate potential persisting effects weeks or months after the experience.

Ongoing Clinical Trials on Psilocybine

  • Study on Psilocybin, Ketamine, and Midazolam for Treating Depression in Cancer Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study of psilocybin therapy for psychological distress in patients with COPD, ALS, multiple sclerosis, or atypical Parkinson’s disorders

    Recruiting

    2 1 1
    Investigated drugs:
    Czechia Denmark The Netherlands Portugal

  • Study on Psilocybin and Midazolam for Reducing Atherosclerosis in Patients with Coronary Artery Disease

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Efficacy of high- and low-dose psilocybin in preventing relapse in adults with severe alcohol use disorder and depressive symptoms after detoxification

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Psilocybin and pimavanserin for adults with major depressive disorder

    Not yet recruiting

    2 1
    Investigated drugs:
    Spain

  • Study of Psilocybin for Patients with Treatment-Resistant Depression

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Austria

  • Study on Psilocybin for Treating Depression in Cancer Patients

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on the Effects of Psilocybin for Patients with Psychogenic Non-Epileptic Seizures (PNES)

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Psilocybin’s Effect on Pain in Fibromyalgia Patients

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Psilocybin for Patients with Treatment-Resistant Depression

    Not recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Psilocybin: The primary psychoactive compound found in certain species of mushrooms, often referred to as 'magic mushrooms'. It is a prodrug that is converted to psilocin in the body, which is responsible for its psychoactive effects.
  • Serotonin 2A receptor (5-HT2AR): A type of receptor in the brain that psilocybin acts on. It plays a role in mood regulation, perception, and consciousness.
  • Neuroplasticity: The brain's ability to form new neural connections and reorganize itself, which is thought to be enhanced by psilocybin.
  • Altered States of Consciousness (ASC): Changes in one's normal waking consciousness, often induced by psychoactive substances like psilocybin. These can include changes in perception, mood, and cognition.
  • Mystical Experience: A profound spiritual or transcendent experience sometimes reported during psilocybin sessions, characterized by feelings of unity, transcendence of time and space, and deep positive mood.
  • Ego Dissolution: A phenomenon where one's sense of self or identity becomes less distinct or temporarily disappears, often reported during high-dose psychedelic experiences.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. In psilocybin studies, this includes measures like peak plasma concentration (Cmax) and elimination half-life.
  • Functional Magnetic Resonance Imaging (fMRI): A neuroimaging technique used to measure brain activity by detecting changes in blood flow. It's used in some psilocybin studies to observe how the drug affects brain function.
  • Ketanserin: A drug that blocks serotonin 2A receptors, sometimes used in psilocybin studies to investigate the role of these receptors in psilocybin's effects.
  • Psychometric Instruments: Standardized tools or questionnaires used to measure psychological attributes or experiences. In psilocybin studies, these might include scales to assess mood, altered states of consciousness, or mystical experiences.

References

  1. https://clinicaltrials.gov/study/NCT06692192
  2. https://clinicaltrials.gov/study/NCT03289949
  3. https://clinicaltrials.gov/study/NCT06319378
  4. https://clinicaltrials.gov/study/NCT06067737
  5. https://clinicaltrials.gov/study/NCT03715127
  6. https://clinicaltrials.gov/study/NCT05592379